Eric Devroe - 13 Jan 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: Chief Operating Officer
Signature: /s/ Adam D. Levy, Attorney-in-Fact
Issuer symbol: ACRV
Transactions as of: 13 Jan 2026
Net transactions value: +$17,218
Form type: 4
Filing time: 15 Jan 2026, 16:38:05 UTC
Previous filing: 18 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Devroe Eric	Chief Operating Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN	/s/ Adam D. Levy, Attorney-in-Fact	15 Jan 2026	0001950573

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRV	Common Stock	Purchase	$17,218	+10,000	+15%	$1.72	75,308	13 Jan 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.719 to $1.7268, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.

Content

The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.719 to $1.7268, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.